Instructions for eflornithine tablets

Eflornithine tablets (eflornithine) is an irreversible inhibitor of ornithine decarboxylase (ODC). It was originally developed to treat African trypanosomiasis. Its application in the field of tumor research has gradually expanded, especially in the field of Neuroblastoma (Neuroblastoma). It has made significant breakthroughs. As an oral drug that precisely interferes with cell proliferation and differentiation, eflornithine tablets have been approved to reduce the risk of recurrence in patients who respond to high-risk neuroblastoma (HRNB) and are an important means of maintenance treatment for the disease.

1. Indications

Eflornithine tablets are mainly targeted at neuroblastoma patients who are still at risk of recurrence after receiving multiple modal treatments (including anti-GD2 immunotherapy, chemotherapy, radiotherapy and stem cell transplantation). Its mechanism of action stems from its selective inhibition of ODC. As a key enzyme in the polyamine synthesis pathway, ODC is up-regulated in a variety of tumor cells and participates in the regulation of DNA stability, cell cycle progression and malignant proliferation. By inhibiting ODC activity, eflornithine reduces the synthesis of polyamine molecules that tumor cells rely on, thereby reducing cell proliferation and enhancing the immune system's ability to recognize and eliminate residual tumor cells.

2. Usage and dosage

As for usage and dosage, individualized dosage based on body surface area (BSA) is the currently recommended standard strategy. For patients with a body surface area greater than 1.5 square meters, regardless of adults or children, the recommended dose is 768 mg, that is, four tablets taken twice a day; if the BSA is between 0.75 and 1.5 square meters, it is recommended to take 576 mg/time (three tablets twice a day); for those with a BSA of 0.5 to 0.75 square meters, two tablets/time are recommended; for the smallest body surface area group (0.25 to 0.5 square meters), it is recommended to take one tablet twice a day. The entire course of maintenance treatment can last up to 2 years, or until the patient encounters termination criteria such as disease recurrence or intolerable side effects.

3. Adverse reactions

It is worth noting that eflornithine may still cause certain adverse reactions during long-term use, including gastrointestinal symptoms (such as diarrhea, nausea), mild hair loss, fatigue, etc., and some patients may show hematological toxicity or hearing abnormalities. Therefore, laboratory examinations and clinical monitoring should be carried out regularly during maintenance treatment. In particular, pediatric patients need to pay special attention to growth, development and nervous system safety.

4. Precautions

In addition, this drug is an oral tablet and should be taken with an appropriate amount of water. It can be taken on an empty stomach or with food. However, in order to ensure stable blood concentration, it is recommended that the daily taking time should be as fixed as possible. Eflornithine has not yet been widely marketed in China, but it has received orphan drug status and accelerated approval from the FDA in the United States. It has also been included in the pediatric neuroblastoma treatment trial plan in Europe, demonstrating its clinical efficacy and long-term treatment potential.

From a treatment logic point of view, the positioning of eflornithine is mainly to continuously suppress the tiny residual lesions of tumors after "clearance", thereby reducing the risk of recurrence. Used in conjunction with immunotherapy drugs such as anti-GD2 antibodies, it is a new direction for the late-stage consolidation treatment of neuroblastoma. Particularly in high-risk populations who are highly susceptible to relapse but have poor prognosis, eflornithine offers an alternative route that can be taken orally and maintained long-term.

Reference materials:https://www.drugs.com/mtm/eflornithine.html